Vaxart's Conference Call Announcement
Vaxart, Inc. (NASDAQ: VXRT) has exciting news for investors and stakeholders. The company is set to deliver a comprehensive business update and reveal its financial performance for the full year that ended on December 31, 2024. This event is scheduled for Thursday, March 20, 2025, and will commence at 4:30 p.m. ET.
Details of the Conference Call
The upcoming conference call provides an excellent opportunity for participants to gain insights from Vaxart’s senior management team. Investors can access the call via various means. To connect, participants can join the conference call using the following numbers: Domestic at (877) 407-0832 and International at (201) 689-8433. Be sure to note the Conference ID 13751819 for easy access.
Webcast Access and Replay Information
In addition to the live call, interested parties can also join the event through a webcast. Vaxart encourages participation through the provided link, which will be accessible right on their website. Furthermore, for those unable to attend the live session, a replay will be available after the event concludes. This allows everyone to catch up on the important discussions and findings shared during the talk.
Submit Your Questions Ahead of Time
As part of fostering a clear communication line with investors, Vaxart allows participants to submit written questions in advance. This initiative helps tailor the discussion to address specific queries, ensuring a thorough exploration of topics critical to stakeholders.
What to Expect from Vaxart
Vaxart is at the forefront of innovative vaccine development, focusing on oral delivery methods that eliminate logistical challenges associated with traditional vaccines. Their commitment to developing oral recombinant vaccines represents a significant advancement in the field, notably through the use of a unique delivery platform that allows for easy storage and transportation without the need for refrigeration.
About Vaxart's Pioneering Technologies
The company’s research and development efforts center around creating vaccines that can protect against various diseases like coronaviruses, noroviruses, and influenza. Moreover, Vaxart is advancing a therapeutic vaccine targeting human papillomavirus (HPV), marking their entry into the immune-oncology sector. Their innovative approach of utilizing pills for vaccination presents a modern twist to traditional vaccine administration.
Intellectual Property and Future Prospects
Vaxart is also taking proactive steps to safeguard its innovations, with extensive patent applications filed both domestically and internationally regarding its proprietary technologies. This commitment to intellectual property not only secures Vaxart’s current developments but positions the company well for future advancements in oral vaccination strategies.
Contact Information for Further Inquiries
For media and investor inquiries, Vaxart’s dedicated spokesperson, Matt Steinberg from FINN Partners, is available to provide additional insights. Interested parties can reach him via email at IR@vaxart.com or by calling (646) 871-8481. Engaging with the media and investors helps Vaxart stay connected to its community while ensuring transparency and accessibility regarding its groundbreaking work.
Frequently Asked Questions
What is the main purpose of Vaxart's upcoming conference call?
The conference call will provide important business updates and share financial results for the year ended December 31, 2024.
How can investors participate in the call?
Investors can participate by calling the provided numbers or joining via a webcast accessible through Vaxart's website.
What innovative solutions does Vaxart offer?
Vaxart focuses on developing oral vaccines, which are designed for easier storage and administration, avoiding refrigeration and reducing needle-stick injuries.
What diseases are Vaxart's vaccines targeting?
The company is working on vaccines for coronaviruses, noroviruses, influenza, and HPV.
Who can be contacted for further information regarding Vaxart?
Matt Steinberg from FINN Partners is available for media and investor queries via email and phone.
